GSK plc Sponsored ADR (GSK)
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
GSK Expands Vaccine Collaboration With Zhifei in China
GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.
GSK extends vaccine partnership with Zhifei in China
GSK PLC (LSE:GSK, NYSE:GSK) has extended its partnership with Chongqing Zhifei Biological Products (Zhifei) to bring its shingles vaccine, Shingrix, to mainland China through 2034. The revised agreement builds on a previous three-year deal and includes exclusive rights for Zhifei to import, distribute, and promote Shingrix.
GSK, China's Zhifei Expand Shingles Shot Collaboration
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration
GSK said on Thursday it has expanded its agreement with China's Zhifei to explore a collaboration with the Chinese vaccines company on the British drugmaker's respiratory syncytial virus (RSV) vaccine, Arexvy.
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo
The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease.
GSK's receives European Commission green light for liquid form of key vaccine
GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine, which protects against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y. This updated formulation eliminates the need for reconstitution before use, simplifying the vaccination process for healthcare providers.
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GSK submits multiple myeloma treatment for approval to the US regulator
The US Food and Drug Administration (FDA) has accepted GSK PLC (LSE:GSK, NYSE:GSK)'s application to review the use of Blenrep (belantamab mafodotin) in treating relapsed or refractory multiple myeloma, a blood cancer. If approved, Blenrep could be combined with bortezomib and dexamethasone (BorDex) or pomalidomide and dexamethasone (PomDex) for patients who have already undergone at least one prior therapy.
GSK's RSV vaccine gets greenlight in Japan
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan's Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related outcomes. The vaccine was previously approved in Japan for individuals aged 60 and older.
GSK’s RSV vaccine gets greenlight in Japan
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan’s Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related outcomes. The vaccine was previously approved in Japan for individuals aged 60 and older. "This approval reflects our ambition to protect people at increased risk from the severe consequences of RSV infection,” GSK chief scientific officer Tony Wood said in a statement. “Adults aged 50-59 with certain underlying medical conditions can face debilitating consequences from RSV, so we are pleased to offer those in Japan a vaccine for the first time." Respiratory Syncytial Virus (RSV) is a common virus that can cause severe illness in adults with underlying health conditions such as COPD, asthma, and chronic heart failure. Happy Creek Minerals CEO Jason Bahnsen joined Steve Darling from Proactive to share exciting findings from the company’s 2024 reconnaissance fieldwork on its Silverboss and Hen-DL properties in south-central British Columbia. During the field season, the company collected 56 rock, 113 soil, and 17 stream sediment samples, which revealed anomalous copper, gold, and silver values, underscoring the potential for discovering significant mineral deposits on both projects. On the Hen-DL property, a standout discovery was a large boulder near the Eureka thrust fault, yielding highly anomalous results for nickel, chromium, cobalt, and platinum. This boulder is believed to originate from a relatively unexplored area of the property, signaling the potential of the mineralized system. Similarly, on the DL property, the team identified a large gabbro-pyroxenite rock boulder, which also exhibited highly anomalous assay results for nickel, chromium, cobalt, and platinum, further pointing to mineralization associated with the Eureka fault area. “These results validate the geological potential of our properties,” said Bahnsen. “We are excited about the discoveries made during the 2024 field season and the opportunities they present for advancing exploration on both the Silverboss and Hen-DL projects.” The company plans to further investigate the source of these boulders and the mineralized zones, emphasizing the significant exploration potential within these promising British Columbia assets.
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
